Author(s)

Zuhal Örnek¹, Metin Işık^2*, Nesibe Karahan Yeşil³, İsmail Doğan⁴, Hatice Şahin⁵, Ali Erdem Baki⁶

¹Department of Pediatrics, Faculty of Medicine, Bülent Ecevit University, Zonguldak, Turkey.
²Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Bülent Ecevit University, Zonguldak, Turkey.
³Department of Rheumatology, Ankara Education and Research Hospital, Ankara, Turkey.
⁴Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Çorum Hitit University, Çorum, Turkey.
⁵Department of Internal Medicine, Faculty of Medicine, Bülent Ecevit University, Zonguldak, Turkey.
⁶Department of Physical Medicine and Rheabilitation, Faculty of Medicine, Bülent Ecevit University, Zonguldak, Turkey.

Disease modifying anti-rheumatic agents are the cornerstone in management of Rheumatoid Arthritis and when used correctly they are life-saving. As the number of the agents increases, detailed guidelines become more and more important for clinicians to set safe and effective regimens. Herein, we combined the EULAR and ACR recommendations for clinicians and also pointed some important facts peculiar to our country.

DMARD, Rational, EULAR, ACR

Örnek, Z. , Işık, M. , Yeşil, N. , Doğan, İ. , Şahin, H. and Baki, A. (2015) Rational Usage of Disease Modifying Anti-Rheumatic Drugs with the Guidance of EULAR and ACR Suggestions. Open Journal of Rheumatology and Autoimmune Diseases, 5, 104-112. doi: 10.4236/ojra.2015.54017.